Injection drug users: The overlooked core of the hepatitis C epidemic

Clinical Infectious Diseases

Volumn 42, Issue 5, 2006, Pages 673-676

  Edlin, Brian R ^a   Carden, Michael R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ILLICIT DRUG;

ALCOHOLISM; COMORBIDITY; DEPRESSION; EPIDEMIC; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; METHADONE TREATMENT; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; VIRUS TRANSMISSION;

DISEASE OUTBREAKS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33144483814     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499960     Document Type: Note

References (50)

1. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S11-9.
2. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-6.
3. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186:1558-64.
4. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330:24-5.
5. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
6. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate [abstract #44]. Oral presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (Boston). 2005. Hepatology 2005; 42(4 Suppl 1):213A.
7. Centers for Disease Control and Prevention (CDC). Disease burden from hepatitis A, B, and C in the United States. Atlanta: CDC, 2005. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm. Accessed 26 October 2005.
8. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-14.
9. Hagan H, Snyder N, Hough E, et al. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002; 79: 579-85.
10. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
11. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406.
12. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19):1-39.
13. Centers for Disease Control and Prevention (CDC). National hepatitis C prevention strategy. Atlanta: CDC, 2001. Available at: http://www.cdc.gov/ ncidod/diseases/hepatitis/c/plan /index.htm. Accessed 26 October 2005.
14. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(5 Suppl 1):S93-8.
15. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(5 Suppl 1):S210-9.
16. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabrai AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138:187-90.
17. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releases from US correctional facilities, 1997. Am J Public Health 2002; 92:1789-94.
18. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005; 40(Suppl 5):S367-72.
19. National Institutes of Health (NIH). Management of hepatitis C: 2002. NIH Consensus State-of-the-Science Statement 2002; 19:1-46. Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm. Accessed 26 October 2005.
20. National Institutes of Health (NIH). Management of hepatitis C. NIH Consensus Statement 1997; 15:1-41. Available at: http://consensus.nih.gov/1997/ 1997HepatitisC105html .htm. Accessed 26 October 2005.
21. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345:211-4.
22. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
23. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-51.
24. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005; 40(Suppl 5):S330-5.
25. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29:159-65.
26. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-8.
27. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 40(Suppl 5):S355-61.
28. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment challenges and opportunities. Clin Infect Dis 2005; 40(Suppl 5): S339-45.
29. Conway B, Grebely J, Tossonian H, Lefebvre D, de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis 2005; 41(Suppl 1):S73-8.
30. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94:153-8.
31. Cournot M, Gilbert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28:533-9.
32. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-35.
33. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Simialar compliance and effect of treatment for chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur Gastroenterol Hepatol 2006; 18:159-66.
34. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-4.
35. Huber M, Weber R, Oppliger R, et al. Interferon alpha-2a plus ribavirin 1000/1200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-9.
36. Baewert A, Ebner N, Thau K, Fischer G. Treatment of hepatitis C/subtype 2 or 3 with pegylated interferon in combination with ribavirin in a population of opioid-dependent patients [abstract 35]. In: Program and abstracts of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence (Orlando, FL). Philadelphia: College on Problems of Drug Dependence, 2005:9.
37. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(Suppl 5): S336-8.
38. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl 5):S325-9.
39. Seal KH, Krai AH, Lorvick J, Gee L, Tsui JI, Edlin BR. Among injection drug users, interest is high, but access low to HCV antiviral therapy. J Gen Intern Med 2005; 20(suppl 1):171.
40. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
41. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636-44.
42. Hagan H, Latka MH, Campbell JV, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006; 42:669-72 (in this issue).
43. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005; 68:55-67.
44. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25:18-32.
45. Geppert CM, Arora S. Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol 2005; 3:937-44.
46. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212-20.
47. Lorvick J, Krai AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91:46-7.
48. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-82.
49. Koch M, Banys P. Liver transplantation and opioid dependence. JAMA 2001; 285:1056-8.
50. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40(Suppl 5):S276-85.